EUVIMEDEUVIMED entdecken
LeserbriefBeobachtungsstudieVergleichsstudie

Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study

Chenyang Shi iD, Yijiong Tan, Shanshan Hu, Yingyi Qin, Yuanjun Tang, Yufan Wang, Guorong Fan

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15552 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Chenyang Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Shanghai Pharmaceutical Association of Clinical Comprehensive Evaluation of Drugs and Research Project on Drug Treatment Pathways.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like PeptidesHumansRetrospective StudiesFemaleMaleInjections, SubcutaneousMiddle AgedProduct Surveillance, PostmarketingAgedTreatment OutcomeBlood GlucoseGlycated HemoglobinDrug Administration ScheduleSemaglutide

Substanzen

Hypoglycemic AgentsGlucagon-Like PeptidesBlood GlucoseGlycated HemoglobinSemaglutide

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Department of Military Health Statistics, Naval Medical University, Shanghai, China.
  • Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.

ORCID-Profile: Chenyang Shi

Förderung

  • Shanghai Pharmaceutical Association of Clinical Comprehensive Evaluation of Drugs and Research Project on Drug Treatment Pathways

Zitieren

APA

Shi, C., Tan, Y., Hu, S., Qin, Y., Tang, Y., Wang, Y., & Fan, G. (2024). Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15552

Vancouver

Shi C, Tan Y, Hu S, Qin Y, Tang Y, Wang Y, et al. Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15552

BibTeX
@article{Shi2024,
  author = {Shi, Chenyang and Tan, Yijiong and Hu, Shanshan and Qin, Yingyi and Tang, Yuanjun and Wang, Yufan and Fan, Guorong},
  title = {Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15552}
}
Kostenlos starten →